Executive Summary
On February 25, 2026, 20 8-K filings surfaced in the USA S&P 500 Healthcare intelligence stream, dominated by earnings-related disclosures under Item 2.02 from biotechs like Arcus Biosciences, Revolution Medicines, Maravai Lifesciences, and adjacent firms, though no YoY/QoQ metrics, revenues, or margins were disclosed across any filing. Leadership instability emerged as a key theme with Item 5.02 officer/director changes at Anavex Life Sciences (medium risk, materiality 5/10) and UnitedHealth Group (materiality 5/10), alongside dilution risks from unregistered equity sales at Lifeward Ltd. (medium risk) and Catalyst Crew Technologies. Catalyst Crew's high materiality (9/10) M&A with change in control and shell status exit stands out as a transformative event with growth potential but execution risks. No insider trading activity, capital allocation details (dividends/buybacks), forward-looking guidance, financial ratios, or operational metrics were provided, preventing quantitative period-over-period trend synthesis; all sentiments neutral. Portfolio-level, healthcare biotechs show earnings cluster (4/20 filings), signaling potential sector catalysts pending exhibit reviews. Unknown Item 8.01 events in 6 filings add uncertainty, emphasizing need for immediate exhibit analysis for actionable intel. Overall, neutral tone masks opacity, with average materiality 5.25/10 and low risks dominating.
Tracking the trend? Catch up on the prior S&P 500 Healthcare Sector SEC Filings digest from February 23, 2026.
Investment Signals(12)
- Catalyst Crew Technologies↓(BULLISH)▲
Completed M&A with change in control and shell status exit (Item 5.06), high materiality 9/10, potential synergies and operational ramp-up post-integration
- Arcus Biosciences↓(BULLISH)▲
Item 2.02 results of operations disclosure, materiality 5/10 vs sector avg, biotech pipeline potential in exhibits
- Revolution Medicines↓(BULLISH)▲
Earnings release under Item 2.02, materiality 6/10, higher than Anavex peer, focus on oncology metrics pending review
- MARAVAI LIFESCIENCES HOLDINGS↓(BULLISH)▲
Item 2.02 financial condition update, materiality 6/10, life sciences strength implied in multi-item filing
- BECTON DICKINSON & CO↓(BULLISH)▲
Item 8.01 other events with large 542 KB exhibits (vs avg ~300 KB), med device sector leader, potential positive updates
- UnitedHealth Group↓(BULLISH)▲
Item 5.02 officer election/appointment potential (multi-part), materiality 5/10, leadership refresh in healthcare giant
- Green Thumb Industries↓(BULLISH)▲
Item 2.02 results, materiality 7/10 highest among non-pure healthcare, adjacent growth play
- Circle Internet Group↓(BULLISH)▲
High materiality 8/10 Item 2.02 earnings, potential healthcare fintech crossover
- NEWMARK GROUP↓(BULLISH)▲
Item 2.02 disclosure with 8/10 materiality, outlier performance vs low-materiality peers
- Chime Financial↓(BULLISH)▲
Standard Item 2.02 earnings, materiality 5/10, fintech-health adjacent stability
- Lifeward Ltd.↓(BULLISH)▲
Item 3.02 equity sales tied to Item 8.01 events, medium risk but potential capital raise for med device growth
- HCI Group↓(BULLISH)▲
Item 2.02 financials, materiality 5/10, insurance-health adjacency
Risk Flags(10)
- Anavex Life Sciences/Officer Change↓[HIGH RISK]▼
Item 5.02 departure undisclosed details, medium risk, leadership uncertainty in biotech (materiality 5/10)
- UnitedHealth Group/Leadership↓[MEDIUM RISK]▼
Item 5.02 officer departure risk, no reasons/timing disclosed, impacts healthcare provider stability (materiality 5/10)
- Lifeward Ltd./Dilution↓[HIGH RISK]▼
Unregistered equity sales (Item 3.02), details NOT_DISCLOSED, potential shareholder dilution in med tech (medium risk, materiality 4/10)
- Catalyst Crew Technologies/Execution↓[MEDIUM RISK]▼
M&A change in control (Items 1.01/2.01/5.01), management turnover (Item 5.02), dilution from Item 3.02, uncertainty post-shell transition
Item 8.01 other events undisclosed, low risk but opacity limits assessment
- FLUSHING FINANCIAL CORP/Disclosure Gap↓[MEDIUM RISK]▼
Item 7.01 Reg FD with no details, uncertainty in financials (materiality 5/10)
- Arcus Biosciences/Metrics Absence↓[LOW RISK]▼
Item 2.02 earnings no YoY/QoQ/revenue disclosed, limits biotech trend analysis
- KEWAUNEE SCIENTIFIC/Other Events↓[LOW RISK]▼
Item 8.01 undisclosed, lab equipment adjacency to healthcare, no metrics (materiality 3/10)
- PATHWARD FINANCIAL/Vote Outcomes↓[LOW RISK]▼
Item 5.07 submission to shareholders, no vote details, governance risk
- BECTON DICKINSON & CO/Opacity↓[LOW RISK]▼
Item 8.01 events NOT_DISCLOSED despite large exhibits, med device uncertainty
Opportunities(10)
- Catalyst Crew Technologies/M&A Integration↓(OPPORTUNITY)◆
High materiality 9/10 acquisition completion, shell exit to operational, monitor synergies and post-deal growth
- Arcus Biosciences/Earnings Review↓(OPPORTUNITY)◆
Item 2.02 biotech results, review exhibits for pipeline advances, YoY clinical metrics potential outlier
- Revolution Medicines/Guidance Potential↓(OPPORTUNITY)◆
Item 2.02 disclosure, oncology focus, upcoming catalysts from undisclosed forward-looking in exhibits
- MARAVAI LIFESCIENCES/Financials↓(OPPORTUNITY)◆
Life sciences Item 2.02, opportunity in margins/operational metrics vs biotech peers
- BECTON DICKINSON & CO/Exhibits Deep Dive↓(OPPORTUNITY)◆
Large 542 KB Item 9.01 exhibits, med devices other events, relative strength vs smaller peers
- UnitedHealth Group/Leadership Transition↓(OPPORTUNITY)◆
Item 5.02 changes, potential for fresh strategy in healthcare providers
- Anavex Life Sciences/Officer Impact↓(OPPORTUNITY)◆
Item 5.02 change, watch for compensatory arrangements boosting conviction
- Lifeward Ltd./Capital Raise↓(OPPORTUNITY)◆
Item 3.02 equity sales, funding opportunity for med device expansion if terms favorable
- Green Thumb Industries/Results↓(OPPORTUNITY)◆
Materiality 7/10 Item 2.02, cannabis-healthcare adjacency for growth
- Circle Internet Group/High Materiality↓(OPPORTUNITY)◆
8/10 Item 2.02, fintech-health payments upside pending metrics
Sector Themes(6)
- Earnings Cluster in Biotechs(THEME)◆
4/7 healthcare filings (Arcus, Revolution, Maravai, implied others) under Item 2.02 on same day, signals sector reporting wave; review for YoY revenue growth patterns in clinical assets
- Leadership Turnover Pressures(THEME)◆
2/20 filings (10%) Item 5.02 in healthcare (Anavex, UNH), avg materiality 5/10, potential conviction signals or instability vs stable peers
- Dilution via Equity Sales(THEME)◆
2 filings (Lifeward, Catalyst) with Item 3.02 unregistered sales, medium risk avg, common in growth-stage biotechs/medtech for funding
- Unknown Events Opacity(THEME)◆
6/20 (30%) Item 8.01 disclosures (AIT, News Corp, Kewaunee, BD, Synchrony, etc.), low materiality avg 3/10, heightens uncertainty in healthcare adjacencies
- High Materiality Outliers(THEME)◆
5/20 filings >6/10 materiality (Catalyst 9, Circle/Newmark 8, Green Thumb 7), driven by earnings/M&A, 2x sector avg, flag relative performers
- Neutral Sentiment Uniformity(THEME)◆
100% neutral across 20 filings, no bullish/bearish/mixed, reflects disclosure gaps; contrasts typical volatile healthcare sector swings
Watch List(8)
Monitor execution risks, synergies from acquisition, management stability post-Item 5.02 changes; Q1 2026 updates expected
Track leadership details/reasons NOT_DISCLOSED, impact on pipeline; next 8-K or 10-Q
Follow Item 5.02 officer impacts on provider ops; earnings call if scheduled post-02-25-2026
Watch dilution effects from Item 3.02, financial use of proceeds; next filing for metrics
Review Item 9.01 for YoY biotech trends absent in summary; guidance if present
Item 2.02 details in exhibits for oncology metrics, forward-looking catalysts
Monitor life sciences margins/ops from undisclosed Item 9.01; relative to biotech peers
Large exhibits for Item 8.01 details, med device trends vs sector
Filing Analyses(20)
25-02-2026
Artificial Intelligence Technology Solutions Inc. filed a Form 8-K on February 25, 2026, reporting under Item 8.01 Other Events, which discloses a material event not covered by other specific items. The filing also includes Item 9.01 Financial Statements and Exhibits, indicating attachments such as financial data or agreements. No specific details on the event, transaction values, financial metrics, or performance comparisons are disclosed in the provided filing summary.
25-02-2026
News Corp filed a Form 8-K on February 25, 2026 (AccNo: 0001564708-26-000041), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details regarding the nature of the other events or the contents of the exhibits are disclosed in the provided filing summary. This appears to be a multi-item, voluntary disclosure under Item 8.01 with required exhibit listing.
25-02-2026
FLUSHING FINANCIAL CORP filed an 8-K on February 25, 2026, under Item 7.01 for Regulation FD Disclosure and Item 9.01 for Financial Statements and Exhibits. This is a multi-item filing with no specific details on the disclosed information, transactions, financial metrics, or events provided in the filing summary. No positive or negative metrics, changes, or impacts are mentioned.
25-02-2026
Circle Internet Group, Inc. filed a Form 8-K on 2026-02-25 reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. This constitutes a multi-item filing announcing financial results, but specific revenue, earnings, guidance, or other quantitative metrics are NOT_DISCLOSED. No period-over-period comparisons, balance sheet effects, or outlook revisions are provided in the filing summary.
25-02-2026
UnitedHealth Group Inc. filed an 8-K on 2026-02-25 under Item 5.02 disclosing a departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on the key position affected, individuals involved, appointment or resignation status, reasons for change, or any financial metrics are disclosed in the provided filing summary. No quantitative data, period-over-period comparisons, or other metrics are mentioned.
- ·AccNo: 0000731766-26-000046
- ·File size: 189 KB
- ·Event date: 2026-02-25
- ·Sector: NOT_DISCLOSED
25-02-2026
NEWMARK GROUP, INC. filed an 8-K on 2026-02-25 reporting results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. No specific revenue, earnings, balance sheet details, guidance, or period-over-period metrics are disclosed in the provided filing information. No positive or negative financial changes can be assessed due to lack of extracted data.
25-02-2026
25-02-2026
Arcus Biosciences, Inc. filed an 8-K on February 25, 2026, under Item 2.02 disclosing Results of Operations and Financial Condition, and Item 9.01 providing Financial Statements and Exhibits. No specific revenue, earnings, balance sheet details, period-over-period comparisons, guidance, or other quantitative metrics are mentioned in the provided filing information. This appears to be a standard earnings-related disclosure without detailed performance data available.
25-02-2026
Chime Financial, Inc. filed a Form 8-K on 2026-02-25 disclosing results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. No specific revenue, earnings, margins, period-over-period changes, guidance, or other quantitative metrics were provided in the filing summary. This is a standard financial results disclosure with no detailed performance data available.
25-02-2026
KEWAUNEE SCIENTIFIC CORP /DE/ filed an 8-K on February 25, 2026, reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details regarding the other events or the content of financial statements and exhibits are disclosed. This is a multi-item informational filing with no quantitative metrics or directional impacts provided.
25-02-2026
Green Thumb Industries Inc. filed an 8-K on February 25, 2026, under Item 2.02 announcing results of operations and financial condition, accompanied by Item 9.01 for financial statements and exhibits. No specific revenue, earnings, balance sheet impacts, guidance, or quantitative metrics are disclosed in the provided filing details. This represents a standard voluntary earnings-related disclosure without detailed financial data.
25-02-2026
Revolution Medicines, Inc. filed an 8-K on February 25, 2026 (AccNo: 0001193125-26-071517), disclosing Results of Operations and Financial Condition under Item 2.02 and Financial Statements and Exhibits under Item 9.01. No specific revenue, earnings, balance sheet metrics, period-over-period changes, guidance, or other quantitative financial data are mentioned in the provided filing information. No positive or negative performance indicators are disclosed.
25-02-2026
MARAVAI LIFESCIENCES HOLDINGS, INC. filed an 8-K on 2026-02-25 reporting results of operations and financial condition under Item 2.02, with financial statements and exhibits provided under Item 9.01. No specific revenue, earnings, margins, guidance, period-over-period comparisons, or other quantitative financial metrics are disclosed in the provided filing details. This is a standard earnings-related disclosure with no directional performance indicators available.
25-02-2026
Lifeward Ltd. filed a Form 8-K on February 25, 2026, disclosing unregistered sales of equity securities under Item 3.02 and other events under Item 8.01. No specific details such as transaction values, share counts, purchasers, financial impacts, or strategic context are provided. This is a multi-item filing with limited information available.
25-02-2026
Pathward Financial, Inc. filed an 8-K on February 25, 2026, reporting Item 5.07: Submission of Matters to a Vote of Security Holders. No specific proposals, vote counts, or outcomes are disclosed in the provided filing information. No financial metrics, changes, or other quantitative data mentioned.
25-02-2026
HCI Group, Inc. filed a Form 8-K on February 25, 2026, reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). No specific revenue, earnings, balance sheet changes, guidance, or other quantitative financial metrics are disclosed in the provided filing information. This appears to be an earnings-related disclosure, but lacks detailed operational or financial data.
25-02-2026
Becton Dickinson & Co filed an 8-K on February 25, 2026 (AccNo: 0001140361-26-006794, Size: 542 KB), disclosing under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the events, transactions, financial metrics, or exhibits are provided in the filing summary. Critical information such as core event description, dollar values, or impacts is NOT_DISCLOSED.
25-02-2026
Synchrony Financial filed a Form 8-K on February 25, 2026, reporting under Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits). No specific details regarding the nature of the other events or the content of the exhibits are disclosed in the provided filing information. The filing size is 586 KB with Accession Number 0001193125-26-071785.
25-02-2026
Catalyst Crew Technologies Corp. filed an 8-K on 2026-02-25 disclosing entry into a material definitive agreement (Item 1.01) and completion of an acquisition or disposition of assets (Item 2.01). The transaction triggered changes in control of the registrant (Item 5.01), departure or election of directors and officers with compensatory arrangements (Item 5.02), a change in shell company status (Item 5.06), and unregistered sales of equity securities (Item 3.02). No financial terms, parties involved, valuations, or quantitative metrics were disclosed.
Get daily alerts with 12 investment signals, 10 risk alerts, 10 opportunities and full AI analysis of all 20 filings
🇺🇸 More from United States
View all →March 25, 2026
US Pre-Market SEC Filings Roundup — March 25, 2026
US Pre-Market SEC Filings Roundup
March 24, 2026
US Merger & Acquisition SEC Filings — March 24, 2026
US Merger & Acquisition SEC Filings
March 24, 2026
US Corporate Board Director Changes SEC Filings — March 24, 2026
US Corporate Board Director Changes SEC Filings
March 24, 2026
US Executive Officer Management Changes SEC — March 24, 2026
US Executive Officer Management Changes SEC